The information contained in this website is for general information purposes only. The information is provided by IXA and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of IXA . We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, IXA takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
Een veilig medicijn tegen hoge bloeddruk helpt kinderen met autisme prikkels beter te verwerken; een studie van Amsterdam UMC bewijst dit. Daarnaast ontwikkelden de onderzoekers een algoritme dat helpt voorspellen bij welke kinderen dit middel werkt. “Deze methode brengt een eerste behandeling op maat in de kinder- en jeugdpsychiatrie”, aldus hoofdonderzoeker Hilgo Bruining. Uit het […]News
Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel discovery platform and a robust pipeline of first in […]News